Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
about
Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developmentsPosttransplant lymphoproliferative disorders following liver transplantation: Where are we now?Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderBurden of de novo malignancy in the liver transplant recipientPosttransplant lymphoproliferative disease after pediatric solid organ transplantationEpstein-Barr virus infection and posttransplant lymphoproliferative disorderPrimary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.Therapeutic options in post-transplant lymphoproliferative disorders.Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004.Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.Recent advances in the treatment of B-cell lymphomaThe interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersSuccessful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumabSuccessful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximabA case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationHow have the past 5 years of research changed clinical practice in paediatric nephrology?Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNSLow-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.The emerging role of rituximab in organ transplantation.Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesPresentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature.Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificitiesTumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease.Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.How I treat EBV lymphoproliferation.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
P2860
Q26775442-1FCD516D-DDAA-42C1-A4F6-204AA181EE0EQ26780262-4AAC9CFF-A8E5-4DFA-8CA8-B74EF0879FBCQ26859114-C5133F05-A0C4-47F0-B81F-E07591FF3C88Q26859216-4DA3D55C-3979-411C-8277-F285E5EF2E23Q26866013-5B99CC99-860D-447E-BC29-4964E146FB5AQ27024229-5B823417-983C-4D4D-9777-DB7E8D723B9CQ30411688-E1499C5C-A751-4785-920E-B174CD03C762Q30455714-80B94B17-1986-4447-A17F-54ECCBF72D81Q33436410-BD6581E7-A27F-47F1-864C-AD893D9E6F38Q33439759-A006B8D6-3A0A-47A9-9832-4B72A4FFA988Q33642308-D6F16A3A-9450-4212-84D0-AC78EB7325AEQ33710720-AB1BB8CE-AB5A-468A-9ACF-03C4B27CBA15Q34056575-2C7066BD-1B58-4DC4-93AF-A8535A023D6BQ34061575-3EED243F-D698-49FB-9E4D-A50203CF5F12Q34062432-6CBDF582-3FDA-4F83-9163-915A2266DB48Q34166602-EFA40D3C-3CC4-4E5F-9560-041AE53CE02FQ34450754-33AE4DA4-A727-40EB-863C-CC3F72F1150FQ34622755-C16E4A29-70C8-40B2-8658-68A154BE2A3BQ34815054-CAEFA83F-741C-4A85-8C96-26221E15CC36Q35082545-F374264B-A455-43EF-AD39-95158B699D68Q35129411-2622B6D3-3DB4-47A7-8ED1-63698E00FBA3Q35170230-5B6BEAA9-9F81-4CF2-BB05-0BC67E0426E2Q35639567-0F894F55-4409-4D8A-AD6F-9F8E17550832Q35849338-96AF00C5-73AA-4988-8716-EF24C14FAA28Q36155260-05337278-D8EC-40D4-B819-6922201CEFBAQ36169107-40E51ACB-FDC0-4907-A12F-6AB919D91876Q36356785-0F10C73B-AE55-4450-A00A-BFB4D4FF7D1DQ36530278-E85DAD1E-A7B1-4528-ADC3-D916836A6DC9Q36684513-9CFB4628-0518-4F54-98CD-14E819C2BF6EQ36724093-BEC30BC7-87A5-4C7C-8EF2-6E071E8BADB0Q36732580-2EA3AB2A-9ACB-444C-8D43-329F0AE43981Q36846805-C8105285-F006-4127-AA7F-85D0B8F76AEEQ36937549-837E9D06-E1B8-4DE2-BBFF-C80B07BB2232Q37012569-FC536EF0-AA15-43A3-BEEC-ECF38D573616Q37319382-53509A2D-6709-4811-B082-934AAFAB837AQ37345359-075ED7CF-14F1-4AB4-AD3D-CF1D69EAC119Q37355856-4F64F4DC-6731-4DA2-AD59-2FF56132B6A9Q37414678-418A171B-DF13-4199-994E-E79220AF1A99Q37426542-D6F5FB7D-EF60-4EA1-859F-3928945A4A75Q37662629-73552E50-91E7-4744-B0C2-16C8B032C23F
P2860
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@en
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@nl
type
label
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@en
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@nl
prefLabel
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@en
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@nl
P2093
P50
P1433
P1476
Efficacy and safety of rituxim ...... ive multicenter phase 2 study.
@en
P2093
Alain Fischer
Anne Moreau
Anne-Marie Stoppa
Augustin Ferrant
Eric Oksenhendler
Etienne Vilmer
Franck Morschhauser
Fritz Offner
Gilles Salles
Jeanne Luce Garnier
P304
P356
10.1182/BLOOD-2005-01-0377
P407
P577
2005-10-27T00:00:00Z